VivaZome Therapeutics is delighted to announce that extracellular vesicles (EVs) from its proprietary human cell line have shown promising results in animal models of Traumatic Brain Injury (TBI). These encouraging findings were presented by VivaZome’s Chief Scientific Officer, Professor David Haylock, at the 2025 conference of the International Society of Extracellular Vesicles (ISEV) recently held in Vienna, Austria. The studies were conducted by our expert collaborators at the Centre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology at University of Queensland (UQ), who have deep expertise in models of brain injury.

The full media release is available here.

The VivaZome poster “VivaZome Proprietary Human Cell-Derived Extracellular Vesicles Enhance Recovery After Moderate Traumatic Brain Injury in a Preclinical Model” is available here.